Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1978 2
1983 1
2008 4
2010 3
2011 4
2012 7
2013 3
2014 2
2015 2
2016 10
2017 5
2018 4
2019 2
2020 2
2021 1
2022 3
2023 5
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Reich DS, et al. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. Lancet Neurol. 2021. PMID: 34418400 Free PMC article. Clinical Trial.
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
A pathway for mitotic chromosome formation.
Gibcus JH, Samejima K, Goloborodko A, Samejima I, Naumova N, Nuebler J, Kanemaki MT, Xie L, Paulson JR, Earnshaw WC, Mirny LA, Dekker J. Gibcus JH, et al. Among authors: goloborodko a. Science. 2018 Feb 9;359(6376):eaao6135. doi: 10.1126/science.aao6135. Epub 2018 Jan 18. Science. 2018. PMID: 29348367 Free PMC article.
Loop extrusion rules: the next generation.
Corsi F, Rusch E, Goloborodko A. Corsi F, et al. Among authors: goloborodko a. Curr Opin Genet Dev. 2023 Aug;81:102061. doi: 10.1016/j.gde.2023.102061. Epub 2023 Jun 22. Curr Opin Genet Dev. 2023. PMID: 37354885 Review.
Pairtools: from sequencing data to chromosome contacts.
Open2C; Abdennur N, Fudenberg G, Flyamer IM, Galitsyna AA, Goloborodko A, Imakaev M, Venev SV. Open2C, et al. Among authors: goloborodko a. bioRxiv [Preprint]. 2023 Feb 15:2023.02.13.528389. doi: 10.1101/2023.02.13.528389. bioRxiv. 2023. PMID: 36824968 Free PMC article. Preprint.
63 results